Picture the first week of January. A letter from a congressional committee lands in your general counsel's inbox, asking about your company's pricing agreement with the Administration. Your CEO is on stage at an investor conference in ten days. Your Q4 call is right behind that. And the only approved language on drug pricing is a paragraph from last spring that nobody wants to read out loud.

That scenario got a lot less hypothetical this month. Democrats won control of the Senate and the House in the November 3 midterms.

The policy desks will cover what passes and what doesn't. This piece is about something smaller and more urgent: the comms team that now has to be ready for a committee letter, a hearing invite or a pricing question on the earnings call, possibly all in the same quarter. We take no political side here. The point is readiness.

The Letters Already Went Out. New Terms Start January 3.

Here's what is on the record. Members of Congress have already sent drugmakers formal written questions about their pricing agreements with the Administration, often called most favored nation, or MFN, agreements.

• December 2025. Ranking members of four committees wrote to AstraZeneca, Eli Lilly, Novo Nordisk and Pfizer asking for the details of each company's agreement, with responses requested by January 5, 2026.

• March 2026. Senate Democrats led by Finance Committee Ranking Member Ron Wyden sent letters to 11 more companies: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis and Sanofi. The questions focused on what Medicaid will pay under those agreements.

• April 2026. The same four ranking members sent an April 13 letter to Merck asking for written responses by April 27, 2026.

Under the 20th Amendment, House and Senate terms end and new ones begin at noon on January 3. I'm not going to guess who chairs what after that.

There's also a recent example of what a pricing hearing looks like. In February 2024, the CEOs of Johnson & Johnson, Merck and Bristol Myers Squibb testified before the Senate HELP Committee on drug prices. Executives in the witness chair, on camera, answering pricing questions in public.

Why Drug Pricing Hearings Matter to Your Comms Team

You don't need a forecast to see the problem.

Picture January for a company that got one of those letters. Its comms team could get a committee letter, a hearing request and a pointed pricing question from an analyst inside the same few weeks. Each one goes to a different audience. Each one gets read by the other two.

That's where it breaks. Not because the answers are hard, but because different teams draft them on different timelines, and the CEO ends up telling investors one version, employees another and lawmakers a third.

How to Build a Congressional Inquiry Response Before the Letter Arrives

If your company got one of those letters, or works in the same space, this is the work to settle before January 3, not after the next letter lands.

• Pricing and access Q&A. The questions you would get from a committee, an analyst, a reporter and your own employees. One set of answers, approved once, written so any of those audiences could read them.

• Executive statements. Short, pre-approved positions your CEO and leadership can say out loud on pricing, access and your agreement with the Administration if you have one. Language that works in a room, not only in a press release.

• A response approval path. Who drafts a reply to a congressional inquiry, who reviews it and who gives the final yes. Legal, government affairs, investor relations and comms all touch it. Decide the order now. We've written about why the review path is where the real work is, and it applies here with higher stakes.

• A calendar that accounts for review. Build the review time into the plan now, including the holiday weeks. If your review calendar for a January launch already runs through November, inquiry readiness runs on the same clock.

• One owner for the narrative. One person whose job is making sure the investor version, the employee version and the lawmaker version are the same story.

None of this requires predicting what a committee will do. It requires having approved communications plan ready for whatever it does.

Your Pharma Communications Plan Needs One Story for Three Rooms

Investors, employees and lawmakers sit in different rooms. They all hear the same CEO. When the story shifts depending on the room, people notice, and the gap becomes the story.

That's why alignment is a workstream, not a reaction. It gets built on purpose, with owners and a calendar, the same way a launch does. A 2027 comms plan finished before November 3 was written before the election results. It doesn't need to be thrown out. It needs the pricing Q&A, the statements and the approval path added before January.

Let's remove the noise and focus on the clear signals. The letters are on the record. The date is set. The rest is preparation.

Build It Before January

Our corporate communications team builds pricing Q&A, executive messaging and approval paths for biotech and pharma companies, on timelines that leave room for review. If January is already on your mind, let's talk.